Treatment of serious infections with moxalactam.
In 93 hospitalized patients, 111 bacterial infections were treated with moxalactam. Eighty-three infections responded well to therapy, nine infections failed to respond to therapy or relapsed, and nine infections showed superinfection with resistant bacteria. The great majority of bacteria isolated had mean inhibitory concentrations below levels readily achieved in plasma, cerebrospinal fluid, bile, abscess fluid, and peritoneal fluid. Among the commonly identified bacteria, only Pseudomonas aeruginosa, enterococci, and Staphylococcus epidermidis had variable sensitivity to moxalactam.
D000038:Abscess / Q000473:pathology; D000328:Adult; D001202:Ascitic Fluid / Q000032:analysis; D001424:Bacterial Infections / Q000188:drug therapy*; D001646:Bile / Q000032:analysis; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000032:analysis / Q000494:pharmacology / Q000627:therapeutic use*; D002555:Cerebrospinal Fluid / Q000032:analysis; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D009070:Moxalactam; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D002511:Cephalosporins; D002513:Cephamycins; D009070:Moxalactam